Association of opioid agonist therapy with lower incidence of hepatitis c virus infection in young adult injection drug users

JAMA Internal Medicine

Volumn 174, Issue 12, 2014, Pages 1974-1981

  Tsui, Judith I ^a,b   Evans, Jennifer L ^c   Lum, Paula J ^c   Hahn, Judith A ^c   Page, Kimberly ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; METHAMPHETAMINE; OPIATE AGONIST; NARCOTIC AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INCIDENCE; INFECTION CONTROL; INJECTION; INTERVIEW; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; RISK REDUCTION; SUBSTANCE USE; UNITED STATES; VIRUS TRANSMISSION; YOUNG ADULT; ADOLESCENT; COMPLICATION; DISEASE TRANSMISSION; INTRAVENOUS DRUG ADMINISTRATION; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; POISSON DISTRIBUTION; PREVENTION AND CONTROL; PROCEDURES; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TRANSMISSION;

ADOLESCENT; ADULT; BUPRENORPHINE; COHORT STUDIES; DISEASE TRANSMISSION, INFECTIOUS; DRUG USERS; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; MALE; METHADONE; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODELS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84919489681     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.5416     Document Type: Article

References (33)

1. Williams IT, Bell BP, KuhnertW, AlterMJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med. 2011;171(3):242-248.
2. Wasley A, Grytdal S, Gallagher K; Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis: United States, 2006. MMWR Surveill Summ. 2008;57(2):1-24.
3. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55(suppl 1):S3-S9.
4. Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis. 2006;42(5):673-676.
5. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-583.
6. Bruggmann P. Accessing hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat. 2012;19(12):829-835.
7. Hahn JA, Page-Shafer K, LumPJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002; 186(11):1558-1564.
8. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74-83.
9. Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978-1988.
10. Centers for Disease Control and Prevention (CDC). Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users: New York, November 2004-April 2007. MMWR Morb Mortal Wkly Rep. 2008;57(19):517-521.
11. Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWRMorb Mortal Wkly Rep. 2011;60(17):537-541.
12. Centers for Disease Control and Prevention. Notes from the field: hepatitis C virus infections among young adults-rural Wisconsin, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(19):358.
13. ChristianWJ, Hopenhayn C, Christian A, McIntosh D, Koch A. Viral hepatitis and injection drug use in Appalachian Kentucky: a survey of rural health department clients. Public Health Rep. 2010; 125(1):121-128.
14. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200(8):1216-1226.
15. Page K, Morris MD, Hahn JA, Maher L, PrinsM. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013;57 (suppl 2):S32-S38.
16. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099-1109.
17. Hadland SE, Kerr T, Li K, Montaner JS,Wood E. Access to drug and alcohol treatment among a cohort of street-involved youth. Drug Alcohol Depend. 2009;101(1-2):1-7.
18. Greene P. Outpatient drug utilization trends for buprenorphine years 2002-2009. May 10, 2010. http://buprenorphine.samhsa.gov/bwns/2010 -presentations-pdf/09-Greene-508.pdf. Accessed March 24, 2014.
19. Gryczynski J, Jaffe JH, Schwartz RP, et al. Patient perspectives on choosing buprenorphine overmethadone in an urban, equal-access system. Am J Addict. 2013;22(3):285-291.
20. Page-Shafer K, Pappalardo BL, Tobler LH, et al. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol. 2008;46(2):499-506.
21. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol. 2001;8(3):200-206.
22. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239-241.
23. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment andHIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. doi:10.1136/bmj.e5945.
24. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303-1310.
25. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003-2011.
26. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison: a high risk of death for former inmates. N Engl J Med. 2007;356(2):157-165.
27. Seal KH, Kral AH, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998-1999. Am J Public Health. 2001;91(11):1842-1846.
28. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62(10): 1157-1164.
29. Center for Substance Abuse Treatment. Federal Guidelines for Opioid Treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
30. CSAM Committee on Treatment of Opioid Dependence. Guidelines for physicians working in California opioid treatment programs. http: //www.csam-asam.org/sites/default/files /CSAMOTPGuideline21Apr09.pdf. Accessed January 2, 2014.
31. DavoliM, Bargagli AM, Perucci CA, et al; VEdeTTE Study Group. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007;102(12):1954-1959.
32. Fischer B, Brissette S, Brochu S, et al. Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. CMAJ. 2004;171 (3):235-239.
33. Subramaniam GA, Fishman MJ,Woody G. Treatment of opioid-dependent adolescents and young adults with buprenorphine. Curr Psychiatry Rep. 2009;11(5):360-363.